Previous 10 | Next 10 |
Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion. Fosun Pharma of Shanghai closed its $182 million in-licensing of China rights to balixafortide with Switzerland's Polyphor AG. Shanghai's I-Mab reported China...
SHANGHAI and SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exc...
Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX PR Newswire SHANGHAI, Sept. 27, 2020 SHANGHAI , Sept. 27, 2020 /PRNewswire/ -- Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical...
Zai Lab Limited (ZLAB) prices Hong Kong secondary listing of 10.56M ordinary shares at HK$562.00 per share for gross proceeds of HK$5.94B.Based on the ratio of one ordinary shares to ADS, the Offer Price translates to approximately US$72.52 per ADS.Underwriters' over-allotment is an addi...
SHANGHAI and SAN FRANCISCO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong Kong secondary listing (the “Hong ...
Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares. Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel's Raziel The...
BAMCO’s 13F portfolio value increased from $20.41B to $27.66B this quarter. Ron Baron added ZoomInfo Tech and increased Zillow Group during the quarter. Their top five positions are at ~22% of the overall portfolio. For further details see: Tracking Ron Baron's BA...
Zai Lab ([[ZLAB]] -8.2%) announced detailed results from the ZEJULA NORA (Phase 3) study, as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-base...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead Tesla (NASDAQ:TSLA) will take top billing this week with its highly-anticipated Battery Day event ...
The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress , demonstrates that niraparib maintenance treatment resulted in a 68 % reduction in the risk of disease progression or death in the ove...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...